- Barrons.com•2 hours ago
Jefferies analyst Brian Abrahams and team contend that the Street missed the importance of last week's NASH data from Gilead Sciences (GILD). They explain why: Following discussions with a NASH key opinion ...
- Market Realist•21 hours ago
The Vanguard Growth Index Fund Investor Shares (VIGRX) is an above-average YTD performer among the 12 funds we've chosen for review in this series.
- Business Wire•21 hours agoGilead Sciences to Present at the Credit Suisse 25th Annual Healthcare Conference on Monday, November 7
Gilead Sciences, Inc. today announced that John F. Milligan, PhD, Gilead’s President and Chief Executive Officer, will participate in a fireside chat at the Credit Suisse 25th Annual Healthcare Conference in Scottsdale, AZ on Monday, November 7 at 8:00 a.m.
Gilead Sciences Inc. (GILD)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||74.59 x 1600|
|Ask||74.60 x 700|
|Day's Range||73.91 - 74.68|
|52wk Range||72.21 - 111.11|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||6.55|
|Avg Vol (3m)||10,591,766|
|Dividend & Yield||1.88 (2.53%)|